AbbVie

ABBV · NYSE

$289.08+$6.40 (+2.26%)TodayMarket closed · Oct 20, 4:05 PM ET

Prev close $282.68

About ABBV

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Illinois and currently employs 57,000 full-time employees. The company went IPO on 2013-01-02. The company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).

Employees: 57,000
Headquarters: North Chicago, Illinois
Listed: Jan 2, 2013
Sector: Health Care
Industry: Biotechnology
Website: abbvie.com

Leadership

AbbVie executives
Name	Title	Since	Age
Robert Michael	—	2017	54
Scott Reents	—	—	57
Azita Saleki-Gerhardt	—	—	61
Timothy Richmond	—	—	58
Roopal Thakkar	—	—	53
Perry Siatis	—	—	50
Nicholas Donoghoe	—	—	44
Jeffrey Stewart	—	—	56
David Purdue	—	—	47
Roxanne Austin	—	—	64
Robert Alpern	—	—	74
William Burnside	—	—	73
Jennifer Davis	—	—	53
Thomas Falk	—	—	66
Thomas Freyman	—	—	70
Brett Hart	—	—	55
Melody Meyer	—	—	67
Susan Quaggin	—	—	61
Edward Rapp	—	—	68
Rebecca Roberts	—	—	72
Frederick Waddell	—	—	71
Liz Shea	—	2024	—

Revenue by product and region

Fiscal year ended Dec 31, 2017: $28.22B total revenue

By product

HUMIRA$18.43B65.3%
IMBRUVICA$2.57B9.1%
HCV$1.27B4.5%
All other$998.00M3.5%
Creon$831.00M2.9%
Other$4.11B14.6%

By region

United States$18.25B64.7%
All other countries$4.08B14.5%
Germany$1.16B4.1%
United Kingdom$807.00M2.9%
Japan$764.00M2.7%
Other$3.16B11.2%

Suppliers and customers

Price correlation is over one year: 1 means the stocks move together, -1 opposite

AbbVie suppliers and customers
Company	Relationship	Country	Correlation
Berkshire Hathaway B BRK.B	Supplier and customer	US	0.96
McKesson Corporation MCK	Customer	US	0.95
AmerisourceBergen Corporation ABC	Customer	US	0.95
SpartanNash Company SPTN	Customer	US	0.90
Monmouth Real Estate Investment A MNR	Supplier	US	0.85
Bristol-Myers Squibb BMY	Supplier and customer	US	0.81
ABA Chemicals A	Supplier	CN	0.78
Voyager Therapeutics, Inc. VYGR	Supplier	US	0.76
Box Inc A BOX	Supplier	US	0.75
Johnson & Johnson JNJ	Customer	US	0.64

Similar companies

Companies in the same industry as AbbVie

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.